Saiba

Executive Summary

Saiba AG is a Swiss biotechnology company founded in 2020 and headquartered in Zurich, pioneering the application of vaccination technology to chronic diseases. The company leverages a proprietary virus-like particle (VLP) platform to develop novel vaccines targeting chronic inflammatory and neurodegenerative conditions, moving beyond the traditional infectious disease focus. By harnessing the immune system's ability to generate sustained responses, Saiba aims to create disease-modifying treatments that could shift the paradigm for conditions such as multiple sclerosis, rheumatoid arthritis, and Alzheimer's disease. The VLP platform offers potential advantages in safety, immunogenicity, and manufacturability, positioning Saiba as an innovative player in the growing field of therapeutic vaccines. Although still in early stages, the company's unique approach and focus on high-need chronic indications have attracted attention from both scientific and investment communities.

Upcoming Catalysts (preview)

• Q1 2027Series A Financing Round70% success
• Q3 2027Lead Program IND Filing50% success
• Q2 2027Research Collaboration Announcement60% success